Baxter Presents Preclinical Data at ISTH on Its Investigational Compound BAX 499 for Potential Subcutaneous Hemophilia Therapy and Final Phase I Data on Recombinant von Willebrand Factor - Drugs.com MedNews
Links shared publicly online about this topic.
- 114total visits
Baxter Presents Preclinical Data at ISTH on Its Investigational Compound BAX 499 for Potential Subcutaneous Hemophilia Therapy and Final Phase I Data on Recombinant von Willebrand Factor - Drugs.com MedNews
Three Baxter Scientists Granted Prestigious ISTH Young Investigators Award Jul 26, 2011 - Baxter International Inc. (NYSE BAX) announced today that new data fro
View full resource at drugs.com
Tags: Hemophilia, Drug, Baxter International, Scientist, Science
Most Recently Shared on July 28, 2011 at 3:14 pm By:
Baxter Presents Preclinical Data at ISTH on Its Investigational Compound BAX 499 for Potential Subcutaneou... http://bit.ly/pjp0Sn #drug
Advertisement
